Foresee Pharmaceuticals, Inc. is a clinical stage, specialty pharmaceutical company that leverages its proprietary controlled-release drug delivery system to develop products to treat chronic debilitating diseases.
- (29.Mar.2019) Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 Mg
- (21.Feb.2019) Foresee Pharmaceuticals Announces Successful Topline Results From Phase 3 Registration Study of LMIS 25 Mg in Prostate Cancer
- (11.Feb.2019) Foresee Pharmaceuticals Enters Exclusive License Agreement With Accord Healthcare
- (26.Nov.2018) Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 Mg (Fp-001) for the Treatment of Advanced Prostate Cancer